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Abstract
Background: The 7th edition of the American Joint Committee on Cancer (AJCC) staging system has
recently been validated and shown to predict survival in patients with intrahepatic cholangiocarcinoma
(ICC). The present study attempted to investigate the validity of these findings.
Methods: A single-centre, retrospective cohort study was conducted. Histopathological restaging of
disease subsequent to primary surgical resection was carried out in all consecutive ICC patients. Overall
survival was compared using Kaplan–Meier estimates and log-rank tests.
Results: A total of 150 patients underwent surgery, 126 (84%) of whommet the present study's inclusion
criteria. Of these 126 patients, 68 (54%) were female. The median length of follow-up was 4.5 years. The
median patient age was 58 years (range: 24–79 years). Median body mass index was 27 kg/m2 (range:
17–46 kg/m2). Staging according to the AJCC 7th edition categorized 33 (26%) patients with stage I
disease, 27 (21%) with stage II disease, five (4%) with stage III disease, and 61 (48%) with stage IVa
disease. The AJCC 7th edition failed to accurately stratify survival in the current cohort; analysis revealed
significantly worse survival in those with microvascular invasion, tumour size of >5 cm, grade 4 disease,
multiple tumours and positive lymph nodes (P < 0.001). A negative resection margin was associated with
improved survival (P < 0.001).
Conclusions: The AJCC 7th edition did not accurately predict survival in patients with ICC. A
multivariable model including tumour size and differentiation in addition to the criteria used in the AJCC
7th edition may offer a more accurate method of predicting survival in patients with ICC.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is a malignant neoplasm
originating from the epitheliocytes of bile ductules.1 It is the
second most common primary malignancy of the liver and has
reported incidences of 0.5–2.0 per 100 000 individuals in the adult
population of the USA.2,3 Recent studies suggest its incidence is
rising worldwide.4 Surgery continues to be the only modality
shown to prolong survival.5–7 One- and 5-year survival rates in
those with unresectable disease are reported to be 23% and 3%,
respectively.8,9 However, post-resection overall survival rates of
70–80% at 1 year7,8 and 30–35% at 5 years7,10 have been reported.
Correct staging to accurately identify patients who would
benefit from major surgical resection is critical to the appropriate
management of these patients. The introduction of unique staging
for ICC in the 7th edition of the American Joint Committee on
Cancer (AJCC) cancer staging system11 was a major step towards
providing exclusive prognostication in Western populations. The
main differences with the 6th edition of the AJCC staging system
were the removal of tumour size from the staging and the inclu-
sion of tumour features such as periductal invasion, vascular inva-
sion and tumour multiplicity. The staging system proposed
was found to be superior to the staging systems suggested by
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Yamasaki12 and Okabayashi et al.13 in its ability to discriminate for
survival utilizing patients in the Surveillance, Epidemiology and
End Results (SEER) database.14 However, the utilization of such an
outcomes database entailed considerable gaps in data and incom-
plete clinical information, including that on tumour–node–
metastasis (TNM) staging (pNx was considered pN0), incomplete
T-staging in some N0M0 patients (63 patients with pTx with poor
survival), and missing information on resection status and
tumour growth type.15 Recently, two multicentre studies16,17 origi-
nating from Europe tried to evaluate the validity of this current
staging system in independent population datasets with equivocal
results.
The primary aim of the current study was to report a single-
centre, large-volume experience of survival outcomes in patients
with ICC submitted to primary curative surgical resection. The
secondary aim was to examine whether or not the 7th edition of
the AJCC staging system accurately predicted survival in such a
cohort.
Materials and methods
Patients
The study was approved by the Mayo Clinic’s Institutional Review
Board. Subsequently, all consecutive patients with ICC who were
treated with primary surgical resection between 1997 and 2011 at
the Mayo Clinic (Rochester, MN, USA) were identified. Patients
with evidence of M1 disease and patients treated with palliative
operations were excluded. A prospective histopathological
re-review of slides was performed by one pathologist (TM). Data
for patients for whom slides were not available for review were
excluded from the analysis.
Clinicopathological variables of interest
Demographic covariates included age, gender, race and body mass
index (BMI) (kg/m2). Histopathological covariates included
tumour growth type, grade, necrosis, invasion (microvascular,
macrovascular and neighbouring organs), multicentricity, hepatic
steatosis or fibrosis, primary sclerosing cholangitis, haemochro-
matosis, cirrhosis and lymph node status. Liver resections were
categorized as major when four or more liver segments were
resected. Vascular resection was categorized as major when the
inferior vena cava or portal vein was reconstructed. The AJCC
staging system (7th edition)11 was used to categorize the T-stage
and N-stage, and to provide overall staging. In addition, the resec-
tion margin was categorized as negative (R0) when the tumour
was not at the inked margin, or as microscopically positive (R1) or
macroscopically positive (R2). Only patients submitted to lymph
node excision were included in the study. Lymph node excisions
included the regional sampling of lymph nodes and lymph node
dissection. Lymph node dissection was defined as the formal
removal of the hilar, periduodenal and peripancreatic lymph
nodes in the right liver and the removal of the hilar and
gastrohepatic nodes in the left liver. The presence of any positive
lymph node was considered to indicate pN1 disease. Overall sur-
vival was calculated as the time from operative resection to the
date of the patient’s death from any cause or last follow-up visit, at
which point data were censored.
Histopathological examination
All resected specimens were subjected to gross and microscopic
pathological examination. Gross evaluation of tumours included
the measurement of tumour size, count of tumour masses, assess-
ment for gross vascular invasion (gross involvement of large
vessels), gross evaluation of the resection margin, and measure-
ment of the distance between the tumour mass and the resection
margin. The tumour growth pattern was classified as being of
mass-forming type, periductal infiltrating type, or intraductal and
mixed mass-forming/periductal infiltrating type, according to the
AJCC guidelines.11 Patients with periductal infiltrating type,
intraductal and mixed mass-forming/periductal infiltrating type
were combined and classified as ‘other’ because the sample size
was small. All specimens were diligently dissected to search for
lymph nodes; all lymph nodes were submitted to microscopic
examination. Microscopic examination of all specimens was per-
formed by a single hepatobiliary pathologist (TM). This included
the evaluation of the submitted haematoxylin and eosin-stained
sections of both the tumour mass and background liver paren-
chyma. Tumours were graded according to the four-tier quantita-
tive grading system adopted by the College of American
Pathologists (CAP).18 Instances of grade 3 and grade 4 disease
were grouped together as ‘high grade’. The total number of lymph
nodes removed and the total number of lymph nodes positive for
metastatic cholangiocarcinoma were recorded.
The background liver parenchyma was evaluated for fibrosis,
steatosis or steatohepatitis, haemosiderosis, and primary
sclerosing cholangitis by standard pathological examination
techniques.19,20
Statistical analysis
Statistical analyses were performed using sas Version 9.2 (SAS
Institute, Inc., Cary, NC, USA). Descriptive statistics were
reported for all study variables as the median with range or as the
count with percentage as appropriate. Survival was estimated for
patients according to the AJCC 7th edition classification using the
Kaplan–Meier method. Similarly, estimates were made for patient
variables, tumour characteristics in addition to AJCC stage, and
surgical variables. A Cox proportional hazards model was used to
assess the association of AJCC 7th edition stage with patient sur-
vival and the concordance index for the model was reported. A
multiple-variable model utilizing patient characteristics was used
to assess survival; another model utilized only tumour character-
istics, and a third used surgical variables. Finally, a single multiple-
variable model was used in the three separate models. Random
forest plots were utilized in the selection of multiple-variable
models in addition to the usual variable selection methods (back-
ward and forward). The final single multiple-variable model was
run incorporating the same variables and in addition the AJCC
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7th edition variable. The concordance index (defined as the gen-
eralization of the area under the curve and as measuring the
predictive ability of a model) was calculated for the models and
various staging systems and reported along with 95% confidence
intervals (CIs). An α-level of 0.050 was considered to indicate
statistical significance.
Results
A total of 150 patients underwent surgical resection for ICC
during the study period. A total of 24 patients (16%) did not
undergo lymph node evaluation and their data were excluded
from the analysis. Demographics, tumour features and surgical
interventions are shown in Table 1.
An R0 resection margin was achieved in 110 (87%) patients; the
median margin width was 4 mm (range: 1–45 mm). Lymph node
dissection was performed in 46 (37%) of the 126 patients submit-
ted to lymph node evaluation. The median number of lymph
nodes removed was three (range: one to 48); the median number
of positive lymph nodes was three (range: one to 18). Pathologi-
cally confirmed positive lymph nodes (pN1) were found in 33
(26%) patients.
Survival in all patients in the study
The median length of follow-up was 4.5 years (range: 5 days to
14.0 years); 64 (51%) patients were alive at the last follow-up. The
median overall survival was 44 months; 1- and 5-year survival
rates of 84% and 43%, respectively, were identified. Data on
median overall survival stratified according to the various stages,
including hazard ratios (HRs), are given in Table 2. None of the
currently available staging systems were able to accurately stratify
survival in this patient cohort (Fig. 1). Univariate analysis showed
that the worsening of survival was statistically significant for the
following variables: tumour size of >5 cm (HR 2.50, 95% CI 1.27–
4.93); multiple tumours (HR 1.79, 95% CI 1.05–3.04); pN1 status
(HR 3.14, 95% CI 1.83–5.38); presence of grade 4 disease (HR
3.72, 95% CI 1.74–7.95), and microvascular invasion (HR 1.87,
95% CI 1.12–3.09) (Table 3). Final stepwise multivariate analysis
showed statistically significantly worse survival in patients with
grade 4 disease (HR 7.84, 95% CI 3.35–18.35), pN1 disease (HR
2.93, 95% CI 1.64–5.21) and microvascular invasion (HR 1.84,
95% CI 1.06–3.21) (Table 3).
Survival according to T (N0M0) classification
Of the 126 patients in whom lymph nodes were evaluated, 93
(74%) were found to have pathologically confirmed node-
negative disease. At the time of last follow-up, 57 (61%) of these
patients were alive. Median overall survival in these patients was
79 months; rates of 1- and 5-year survival amounted to 92% and
57%, respectively. The various staging systems did not distribute
T-stages equally. Data on median overall survival including HRs
are given in Table 2. None of the currently available staging
systems were able to accurately stratify survival in this sub-cohort.
Upon univariate analysis, only the presence of grade 4 disease was
correlated with poor survival (HR 4.23; P = 0.004) (Table 3).
Given the small sample size of patients with pN0 disease and their
lower mortality, multivariate analysis was not performed in this
subset of patients.
Comparison of survival in pN0 and pN1 patients
The presence of positive lymph nodes (pN1) correlated with poor
survival. The HR for having any positive lymph node was 3.14
(95% CI 1.50–5.40) (P < 0.001). Median overall survival in
patients with pN1 disease was 20 months; 1- and 5-year survival
rates amounted to 61% and 13%, respectively. Having three or
more positive lymph nodes was associated with even worse sur-
vival (P < 0.001). An analysis of the impact of lymph node ratio
(number of positive nodes/total number removed) on survival
showed that a ratio of >0.1 correlated with poor survival (HR
1.34, 95% CI 1.20–1.50).
Levels of concordance and 95% CIs were calculated for the
different staging systems and for the multivariable models
(Fig. 2). Model 1 included a tumour size of >5 cm in addition to
Table 1 Patient demographics, tumour features and liver resection
data in 126 patients with intrahepatic cholangiocarcinoma
Demographics
Length of follow-up, median (range) 4.5 years (5 days
to 14 years)
Age, years, median (range) 58 (24–79)
Gender, female, n (%) 68 (54%)
Body mass index, kg/m2, median (range) 27 (17–46)
Cirrhosis, n (%) 9 (7%)
Primary sclerosing cholangitis, n (%) 5 (4%)
Haemochromatosis, n (%) 2 (2%)
Tumour features and liver resection
Tumour size, cm, median (range) 7.0 (0.7–20.0)
Growth type, n (%)
Mass-forming 83 (66%)
Other (periductal, intraductal and combined) 43 (34%)
High grade (grades 3 and 4) 68 (54%)
Multiple tumours 44 (35%)
Invasion, n (%)
Macrovascular 11 (9%)
Microvascular 65 (52%)
Periductal 41 (33%)
Perineural 46 (37%)
Direct invasion 11 (9%)
Fibrosis 49 (39%)
Steatosis 19 (15%)
Major liver resection, n (%) 56 (44%)
Major vascular resection, n (%) 14 (11%)
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AJCC 7th edition staging and reached a concordance of 0.66 (95%
CI 0.58–0.74). Model 2 included tumour size of >5 cm, grade 4
disease, multiple tumours, periductal invasion, pN1 disease and
microvascular invasion, and reached a concordance of 0.71 (95%
CI 0.62–0.79).
Discussion
This study demonstrates that the current staging systems (the
AJCC 6th edition, AJCC 7th edition, and those devised by
Okabayashi et al.13 and Yamasaki12) do not accurately stratify sur-
vival in this patient cohort. However, the univariate analysis of
survival outcomes demonstrated that multiplicity of disease, size
and vascular invasion were key prognostic factors for survival, as
were angiolymphatic invasion, lymph node status and grade of
tumour. Multivariate analysis demonstrated that only a resection
margin of >5 cm, grade 4 disease, and lymph node status were
significant factors. In this study, the median length of overall
survival following surgical resection for ICC was 44 months,
which is higher than survival times reported in other studies,
despite the higher rate of major resection.
There were several differences in survival between this cohort
and the cohort15 used to propose the AJCC 7th edition, which may
account for the survival differences observed. For example, the
current study included only patients in whom lymph node status
was evaluated, among whom the proportion of patients with
positive-margin surgical resection was very small and in whom
survival was notably higher and follow-up more extended in
comparison with those in the cohort sourced from the SEER
database.14
This study found that tumour size and grade 4 disease may play
significant roles in the prognosis of ICC patients after surgical
resection. The multivariable model, which included tumour size
and grade in addition to variables in the AJCC 7th edition,
achieved a concordance of 0.71.
Currently, lymph node disease in ICC patients is reported as
either present or absent in all of the staging systems available. This
study not only confirmed the presence of pN1 disease to be asso-
ciated with poor survival, but further analysis suggested that
increasing the lymph node ratio (positive lymph nodes/total
number removed) correlated with worse survival. The prognostic
Table 2 Cox proportional hazard ratios and overall median survival for various tumour–node–metastasis (TNM) staging systems
TNM stage n (%) Median OS, months HR (95% CI) P-value
AJCC 7th edn11 I 33 (22%) 70 Referent
II 27 (18%) 90 0.95 (0.42–2.11) 0.895
III 5 (3%) Not reached 0.0 (0.0–2.10) 0.160
IVa 61 (40%) 32 2.35 (1.26–4.37) 0.007
AJCC 6th edn21a I 36 (31%) 70 Referent
II 20 (27%) 66 0.99 (0.43–2.23) 0.975
IIIa 17 (15%) 41 1.33 (0.51–3.46) 0.552
IIIb 11 (9%) 99 0.93 (0.31–2.81) 0.899
IIIc 33 (28%) 22 3.31 (1.70–6.42) <0.001
Okabayashi et al.13a I 40 (34%) 79 Referent
II 20 (17%) 66 1.07 (0.47–2.43) 0.879
IIIa 24 (21%) 81 1.46 (0.66–3.24) 0.346
IIIb 33 (28%) 20 3.59 (1.87–6.88) <0.001
Yamasaki12 I 1 (1%) 79 Referent
II 48 (41%) 66 – –
III 32 (27%) 81 1.23 (0.60–2.51) 0.570
IVa 36 (30%) 20 3.17 (1.75–5.74) <0.001
AJCC 7th edn T (N0M0) staging
T-stage n (%) Median OS, months HR (95% CI) P-value
T1 37 (29%) 70 1.00 (referent)
T2a 14 (11%) Not attained 0.39 (0.10–1.38) 0.145
T2b 26 (21%) 41 1.56 (0.65–3.75) 0.323
T3 8 (6%) Not attained 0.0 0.182
T4 41 (33%) 66 1.6 (0.72–3.53) 0.251
aMissing staging information in nine patients.
AJCC, American Joint Committee on Cancer; CI, confidence interval; HR, hazard ratio; N0M0, node-negative and metastasis-negative disease; OS,
overall survival.
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importance of lymph node ratio to survival has been shown in one
prior study, which reported that an increasing lymph node ratio
was associated with a poorer prognosis.21 However,a recent analysis
based on data from the SEER database14 reported that data on
lymph node status were available for only 49% of patients submit-
ted to surgery for ICC, and that a histological evaluation of lymph
nodes was performed in only 14% and the median number of
lymph nodes harvested was two.21 Furthermore, there is no con-
sensus on the optimal number of lymph nodes that should be
harvested for accurate lymph node staging. Although the role of
lymph node sampling is undetermined, these data suggest that
routine lymph node evaluation is warranted in patients with ICC in
order to elucidate the impact of lymph node status on prognosis.
In this study, resection margin status was an important deter-
minant of prognosis in ICC patients. The current analysis showed
that negative surgical margin status correlates with improved sur-
vival and similar findings have been reported in multiple prior
studies.7,10,22 However, the optimal margin width in patients with
R0 resection remains undetermined. The present findings were
corroborated by those of a recent study that reported a margin
width of >5 mm in pN0 patients as an independent predictor of
improved survival.23 Efforts should be made to obtain a 5-mm
negative surgical margin.
The present study has several limitations. Its retrospective
design and the fact that it was conducted at a single tertiary care
centre may have led to some degree of selection bias. The sample
size, although relatively large for a single centre, may not have
been sufficiently powered to accurately predict survival in various
TNM staging models. Furthermore, the impact of chemotherapy
was not assessed. Nonetheless, this is the first single-centre study
from the USA to have evaluated the validity of the AJCC 7th
edition staging system. Furthermore, only completely staged
patients were included in the survival analysis and all histological
subtypes were included. Given the high proportion of patients
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Figure 1 Kaplan–Meier survival plots comparing various staging systems. AJCC, American Joint Committee on Cancer; LCSGJ, Liver
Cancer Study Group of Japan
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submitted to lymph node evaluation, it was feasible to study the
impact of the number of positive lymph nodes on survival. The
strengths of the study include the fact that all histopathological
examinations were conducted by a single pathologist, which
enabled the accurate staging of patients and a prolonged
follow-up of 4.5 years.
To summarize, none of the available staging systems were able
to accurately stratify survival in the current cohort. The Mayo
Clinic staging model added a tumour size of >5 cm and the pres-
ence of grade 4 disease to the AJCC 7th edition model and
improved concordance to only 0.71. Further studies are needed to
test the validity of these findings. As none of the published studies
show favourable groupings in terms of the various staging
systems, multicentre studies from the USA that include com-
pletely staged patients may help to overcome this barrier. Further-
more, such multicentre trials will probably give sufficient power to
Table 3 Univariate and multivariate hazard ratios for node-negative and metastasis-negative (N0M0) patients and all patients
Variables N0M0 patients (n = 93) All patients (n = 126)
n Median
survival,
months
HR (95% CI) P-value n Median
survival,
months
HR (95% CI) P-value
Univariate analysis
Tumour size of >5 cm Yes 58 60 1.91 (0.87–4.20) 0.102 Yes 88 38 2.50 (1.27–4.93) 0.008
No 35 99 No 38 99
Grade 4 disease Yes 6 14 4.23 (1.58–11.28) 0.004 Yes 10 6 3.72 (1.75–7.95) <0.001
No 87 81 No 116 49
Periductal invasion Yes 28 66 1.75 (0.85–3.61) 0.123 Yes 41 38 1.61 (0.96–2.69) 0.064
No 65 84 No 85 60
Direct invasion Yes 11 70 0.85 (0.30–2.41) 0.762 Yes 18 43 1.21 (0.61–2.39) 0.582
No 82 99 No 108 49
Macrovascular invasion Yes 9 49 1.36 (0.48–3.86) 0.561 Yes 11 44 1.32 (0.60–2.89) 0.491
No 84 81 No 115 49
Microvascular invasion Yes 37 66 1.12 (0.57–2.17) 0.741 Yes 60 32 1.87 (1.13–3.09) 0.016
No 56 79 No 66 70
Multiple tumours Yes 30 81 1.40 (0.67–2.92) 0.362 Yes 38 31 1.79 (1.05–3.04) 0.031
No 63 79 No 88 57
Positive lymph nodes – – – – – Yes 33 20 3.14 (1.83–5.39) <0.001
No 93 79
Multivariate analysis
Grade 4 disease Yes 10 6 7.84 (3.35–18.35) <0.001
No 116 49
Positive lymph nodes Yes 33 20 2.93 (1.65–5.21) <0.001
No 93 79
Microvascular invasion Yes 60 32 1.85 (1.06–3.22) 0.030
No 66 70
Multiple tumours Yes 38 31 1.68 (0.96–2.92) 0.067
No 88 57
Periductal invasion Yes 41 38 1.53 (0.87–2.68) 0.136
No 85 60
Tumour size of >5 cm Yes 88 38 1.51 (0.75–3.06) 0.248
No 38 99
Resection margin – – – – – R0 110 66 – –
Non-R0 16 25
Margin width – – – – – >5 mm 70 99 <0.001
<5 mm 56 38
CI, confidence interval; HR, hazard ratio; N0M0, node-negative and metastasis-negative disease.
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support the development of a model that will accurately predict
the survival of ICC patients in the USA.
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